ProImmune Unveils New 18,000 sq ft Global Headquarters to Drive Growth in Immunology and Life Science Innovation

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Oct 22 2025

0mins

Source: Businesswire

New Headquarters Announcement: ProImmune Ltd has opened its new global headquarters at Oasis Park, Oxford, which will enhance its operational capacity and ability to serve clients worldwide.
Investment in Innovation: The 18,000 sq ft facility includes state-of-the-art laboratories aimed at accelerating the development of the REVEAL® Immunogenicity System and expanding the Ankyron® target binding reagent platform.
Focus on Scientific Excellence: Dr. Nikolai Schwabe, CEO of ProImmune, emphasized the company's commitment to scientific excellence in immunology and global health through this investment.
Support for Therapy Development: The new headquarters will enable ProImmune to deliver world-class products and services, aiding partners in developing safer and more effective therapies for patients globally.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free